Buscopan Compositum Solution for Injection

Land: Irland

Sprache: Englisch

Quelle: HPRA (Health Products Regulatory Authority)

Kaufe es jetzt

Fachinformation Fachinformation (SPC)
14-12-2022
DSU DSU (DSU)
17-03-2023

Wirkstoff:

Hyoscine butylbromide; Metamizole

Verfügbar ab:

Boehringer Ingelheim Vetmedica GmbH

ATC-Code:

QA03DB04

INN (Internationale Bezeichnung):

Hyoscine butylbromide; Metamizole

Dosierung:

4/500 milligram(s)/millilitre

Darreichungsform:

Solution for injection

Verschreibungstyp:

POM: Prescription Only Medicine as defined in relevant national legislation

Therapiebereich:

butylscopolamine and analgesics

Berechtigungsstatus:

Authorised

Berechtigungsdatum:

1991-10-01

Fachinformation

                                BUSCOMP-SPC-B-16
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Buscopan Compositum Solution for Injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
Active substance
Butylscopolamine bromide 4mg
Metamizole 500mg
Excipients
Phenol (as preservative) 5mg
For a full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Solution for injection
A slightly yellow solution
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES_ _
Cattle (adult), horses and dogs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES_ _
As an aid in the control of pain associated with simple equine colic
and as a diagnostic aid in more severe equine colics.
For the control of diarrhoea in cattle, horses and dogs particularly
when pain or abdominal discomfort is present.
For the control of pain associated with urinary obstruction in horses
and dogs.
4.3
CONTRAINDICATIONS
_ _
_ _
_ _
Due to a risk of local reactions do not use the intramuscular route in
horses.
Do not use in case of hypersensitivity to the active substance or to
any of the
excipients.
Do not use in horses suffering from paralytic ileus.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None
BUSCOMP-SPC-B-16
Page 2 of 5
4.5
SPECIAL PRECAUTIONS FOR USE_ _
(I) SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Due to the risk of anaphylactic shock metamizole-containing solutions
should
be administered slowly when given intravenously.
(II) SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
PRODUCT TO ANIMALS
Take care to avoid self-injection. In a very small number of people,
metamizole can cause reversible, but potentially serious
agranulocytosis and
other reactions such as skin allergy. Avoid use of the product if you
are
known to be sensitive to pyrazolones, or are sensitive to aspirin.
Wash any
splashes from the skin. If accidental self-injection occurs, seek
medical
advice and show the Doctor the product packaging.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
In horses, a slight transient increase in heart rate may b
                                
                                Lesen Sie das vollständige Dokument
                                
                            

Suchen Sie nach Benachrichtigungen zu diesem Produkt